NCT06617923
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 52 words
- Enrollment closed, study ongoing
- Secondary endpoints: details revised at 1 of 2 entries
- Site details revised at 2 of 2 sites
- Minor Study sites: 1 to 2v8
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Feb 2025 to Feb 6, 2025
- Minor Start date: Jan 2025 to Feb 2025
- Study title expanded, about 6 words
- Minor Start date: Dec 2024 to Jan 2025v4
Show 2 earlier versionsHide 2 earlier versions
- Minor Start date: Nov 2024 to Dec 2024v3
- Minor Start date: Oct 2024 to Nov 2024v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Objective Response Rate (ORR)
Timeframe: 3 years
Secondary (2)
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Frequency of Grade 3 and 4 Adverse Events
Arms and interventions
TreatmentExperimental
Senaparib 80mg Temozolomide 20mg
Drugs: Senaparib, Temozolomide
Sites
2 sites in 1 country